SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendys is experiencing a massive surge in retail interest and trading volume, with the community actively speculating about a short squeeze similar to past meme stock movements. Investors are highlighting the company's dividend yield and buyout potential as reasons to hold, while social media chatter focuses on aggressive buying to combat short-side institutional pressure.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense selling pressure as shares drop toward two-year lows, driven by community concerns over consistent dilution and the stock's weakening correlation with Bitcoin. Investors are heavily debating whether the current price represents a generational buying opportunity or a structural collapse, with many focused on the stock's critical support levels and the risk of further capitulation.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals is attracting intense community interest as investors speculate on a potential buyout, driven by CEO Kevin Tang's significant personal share acquisitions and a new strategic focus. Discussions highlight a mix of optimism regarding recent clinical data and frustration over ongoing management silence, while traders closely monitor heavy volume and short-covering activity for signs of a major move.

Corning, Inc. engages in the provision of glass for notebook computers, flat panel desktop monitors, display televisions, and other information display applications, carrier network and enterprise network products for the telecommunications industry, ceramic substrates for gasoline and diesel engines in automotive and heavy-duty vehicle markets, laboratory products for the scientific community and polymer products for biotechnology applications, optical materials for the semiconductor industry and the scientific community, and polycrystalline silicon products and other technologies. It operates through the following segments: Optical Communications, Display, Specialty Materials, Automotive, and Life Sciences. The Optical Communications segment is classified into two main product groupings: carrier and enterprise network. The carrier network group consists of products and solutions for optical-based communications infrastructure for services such as video, data, and voice communications. The enterprise network group consists primarily of optical-based communication networks sold to businesses, governments, and individuals for their own use. The Display Technologies segment manufactures glass substrates for flat panel displays, including organic light-emitting diodes and liquid crystal displays that are used primarily in televisions, notebook computers, desktop monitors, tablets, and handheld devices. The Specialty Materials segment is involved in the manufacture of products that provide material formulations for glass, glass ceramics and crystals, and precision metrology instruments and software. The Automotive segment manufactures ceramic substrates and filter products for emissions control in mobile applications around the world as well as technical glass and optic products and solutions for the interior and exterior of vehicles. The Life Sciences segment develops, manufactures, and supplies laboratory products. The company was founded by Amory Houghton Sr. in 1851 and is headquartered in Corning, NY.

Corning, Inc.

Corning is trending due to its pivotal role as a supplier of fiber optic and connectivity solutions essential for AI data center infrastructure, bolstered by recent multi-billion dollar partnerships with major hyperscalers. Community members are actively debating its long-term potential as a 'picks and shovels' play, with many highlighting the shift toward photonics as the necessary solution for scaling AI clusters where traditional copper infrastructure hits physical limits.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is facing significant volatility ahead of its first post-IPO earnings report, with the community closely tracking a massive upcoming insider share unlock and the stock's high valuation relative to its revenue. Investors are heavily divided, with some betting on a squeeze fueled by major partnerships with OpenAI and AWS, while others argue that the high price-to-sales ratio and reliance on a limited customer base suggest a potential sharp repricing.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

ABVX is experiencing intense volatility following the release of Phase 3 maintenance data, where strong efficacy results were overshadowed by the disclosure of malignancy cases in the high-dose arm. While management and some analysts downplay these events as unrelated statistical noise, the market is actively debating potential regulatory hurdles, such as black box warnings, and questioning the likelihood of an imminent buyout.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion is seeing heightened investor attention following a pair of executive orders from the White House that prioritize quantum technology and national security, a move further bolstered by CEO Matt Kinsella's direct participation in the event alongside major industry players. While community members are actively debating the implications of a recently rescheduled technical webinar and upcoming Russell index inclusion, much of the discussion focuses on Infleqtion's unique positioning in quantum sensing and its perceived long-term growth potential compared to sector peers.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is experiencing heightened investor activity and volatility as the community eagerly awaits trailer reveals and the commencement of pre-orders for the highly anticipated Grand Theft Auto VI. Traders are closely monitoring the upcoming earnings report, with sentiment split between optimism over the November launch window and concerns regarding forward-looking guidance and potential launch delays.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with mobility drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, and taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting carriers with shippers on its platform, and gives carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber Technologies is currently seeing heightened social media activity driven by reports that the company has implemented spending caps on internal AI coding tools after exhausting its annual budget, alongside ongoing investor chatter about institutional accumulation. While some retail traders express frustration with recent price consolidation and daily volatility, others remain bullish, citing the company's platform growth, robust free cash flow, and potential tailwinds from upcoming major sporting events.

Sunrun, Inc. engages in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems. It sells solar service offerings and installs solar energy systems for homeowners. Customers can access its products through three channels: direct-to-consumer, solar partnerships, and strategic partnerships. The company was founded by Edward Harris Fenster, Robert Nat Kreamer, and Lynn Michelle Jurich in January 2007 and is headquartered in San Francisco, CA.

Sunrun Inc

Sunrun is surging as investors react to a strategic partnership with Tesla and Renew Home to create a massive 16-gigawatt virtual power plant using existing home energy devices to address AI data center power demand. While some community members are betting on a major short squeeze and long-term utility-like growth, others remain cautious, debating whether this is a genuine infrastructure breakthrough or a transient hype cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings

BioCryst Pharma (NASDAQ:BCRX) reported strong Q1 earnings, reaffirmed FY2026 sales guidance, and received positive price target changes from analysts.read more...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Releases Earnings Results, Misses Expectations By $3.04 EPS

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($2.98) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the...

BioCryst Pharmaceuticals (NASDAQ:BCRX) Price Target Cut to $16.00 by Analysts at Needham & Company LLC

Needham & Company LLC dropped their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research report on Wednesday...

BioCryst Pharmaceuticals Q1 Earnings Call Highlights

BioCryst Pharmaceuticals (NASDAQ:BCRX) reported what executives described as a strong start to 2026, driven by continued growth of hereditary angioedema (HAE) therapy ORLADEYO and progress across its development pipeline, while also flagging a manufacturing issue that will delay initial fulfillment...

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates

BioCryst (BCRX) delivered earnings and revenue surprises of -150.00% and +0.06%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

BioCryst Pharmaceuticals (BCRX) Projected to Post Earnings on Wednesday

BioCryst Pharmaceuticals (NASDAQ:BCRX) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Rating of "Moderate Buy" by Analysts

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the thirteen analysts that are presently covering the stock...

Phocas Financial Corp. Takes Position in BioCryst Pharmaceuticals, Inc. $BCRX

Phocas Financial Corp. acquired a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The...

SG Americas Securities LLC Sells 102,210 Shares of BioCryst Pharmaceuticals, Inc. $BCRX

SG Americas Securities LLC lessened its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 44.7% in the 4th quarter, according to its most recent Form 13F filing with the SEC...

Aberdeen Group plc Buys Shares of 913,593 BioCryst Pharmaceuticals, Inc. $BCRX

Aberdeen Group plc acquired a new position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange...

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

Nasdaq, S&P 500 Futures Rise Ahead Of PMI Data, Iran Tensions Cap Risk Appetite: Why NVDA, GME, AAOI, BCRX Are Keeping Traders Engaged Today

Equity

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$0.16	--	--	N/A
Q1 '26	$0.04	-$2.98	-6831.88%	MISSED
Q4 '25	$0.05	$1.12	2220.04%	BEAT
Q3 '25	$0.04	$0.06	50.75%	BEAT
Q2 '25	$0.01	$0.02	185.71%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

BCRXBiocryst Pharmaceuticals Inc.

Upcoming Earnings: Q2 '26

Historical Earnings

Latest BCRX News